Skip to main content
SpringerLink
Log in

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas

  • Short Communication
  • Sarcoma, Combination Chemotherapy
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Akahoshi Y, Takeuchi S, Chen SH, Nishimoto T, Kikuike A, Yonezawa H, Yamamuro T (1976) The results of surgical treatment combined with intra-arterial infusion of anti-cancer agents in osteosarcoma. Clin Orthop: 103–106

  2. Creagan ET, Hahn RG, Ahmann DL, et al (1976) A comparative clinical trial evaluating the combination of adriamycin, DTIC and vincristine, the combination of actinomycin D, cyclophosphamide, vincristine, and a single agent, methyl-CCNU in advanced sarcomas. Cancer Treat Rep 60: 1385–1387

    Google Scholar 

  3. Creagan ET, Edmonson JH, Hahn RG, et al (1978) A preliminary study of cyclophosphamide (NSC-2671), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388) and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomas. Med Pediatr Oncol 4: 85–86

    Google Scholar 

  4. Eagan RT, Frytak S, Creagan ET, Richardson RL, Coles DT, Jett JR (1985) Differing response rates and survival between squamous and non-squamous non-small cell lung cancer: comparison of CAP versus MAP. Cancer Treat Rep (in press)

  5. Edmonson JH, Hahn RG, Schutt AJ, Bisel HF, Ingle JN (1983) Further phase II study of cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas. Med Pediatr Oncol 11: 319–321

    Google Scholar 

  6. Edmonson JH, Creagan ET, Kvols LK, Richardson RL, Rubin J, Green SJ (1984) Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin and cisplatin (CAP) in advanced sarcomas. Med Pediatr Oncol 12: 264–266

    Google Scholar 

  7. Evans, AE (1961) Mitomycin C. Cancer Treatment Rep 14: 1–19

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    John H. Edmonson, Harry J. Long, Ronald L. Richardson & Edward T. Creagan

  2. the Cancer Center Statistical Unit, Rochester, MN, USA

    Stephanie J. Green

Authors
  1. John H. Edmonson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry J. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald L. Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edward T. Creagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephanie J. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edmonson, J.H., Long, H.J., Richardson, R.L. et al. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother. Pharmacol. 15, 181–182 (1985). https://doi.org/10.1007/BF00257535

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257535

Keywords

Search

Navigation